Nathalie Cartier-Lacave to Brain
This is a "connection" page, showing publications Nathalie Cartier-Lacave has written about Brain.
Connection Strength
0.442
-
Djelti F, Braudeau J, Hudry E, Dhenain M, Varin J, Bi?che I, Marquer C, Chali F, Ayciriex S, Auzeil N, Alves S, Langui D, Potier MC, Laprevote O, Vidaud M, Duyckaerts C, Miles R, Aubourg P, Cartier N. CYP46A1 inhibition, brain cholesterol accumulation and neurodegeneration pave the way for Alzheimer's disease. Brain. 2015 Aug; 138(Pt 8):2383-98.
Score: 0.262
-
N?brega C, Mendon?a L, Marcelo A, Lamazi?re A, Tom? S, Despres G, Matos CA, Mechmet F, Langui D, den Dunnen W, de Almeida LP, Cartier N, Alves S. Restoring brain cholesterol turnover improves autophagy and has therapeutic potential in mouse models of spinocerebellar ataxia. Acta Neuropathol. 2019 11; 138(5):837-858.
Score: 0.086
-
Fol R, Braudeau J, Ludewig S, Abel T, Weyer SW, Roederer JP, Brod F, Audrain M, Bemelmans AP, Buchholz CJ, Korte M, Cartier N, M?ller UC. Viral gene transfer of APPsa rescues synaptic failure in an Alzheimer's disease mouse model. Acta Neuropathol. 2016 Feb; 131(2):247-266.
Score: 0.067
-
Zerah M, Piguet F, Colle MA, Raoul S, Deschamps JY, Deniaud J, Gautier B, Toulgoat F, Bieche I, Laurendeau I, Sondhi D, Souweidane MM, Cartier-Lacave N, Moullier P, Crystal RG, Roujeau T, Sevin C, Aubourg P. Intracerebral Gene Therapy Using AAVrh.10-hARSA Recombinant Vector to Treat Patients with Early-Onset Forms of Metachromatic Leukodystrophy: Preclinical Feasibility and Safety Assessments in Nonhuman Primates. Hum Gene Ther Clin Dev. 2015 Jun; 26(2):113-24.
Score: 0.016
-
Sevin C, Cartier-Lacave N, Aubourg P. Gene therapy in metachromatic leukodystrophy. Int J Clin Pharmacol Ther. 2009; 47 Suppl 1:S128-31.
Score: 0.010